EMA, Drug Giants Join Push To Reform Vaccine Monitoring

Law360, New York (November 26, 2013, 5:37 PM EST) -- The European Medicines Agency and Pfizer Ltd., Novartis Pharma AG and other drugmakers joined an initiative Tuesday designed to create a continentwide framework for assessing the benefits and drawbacks of vaccines after they have been approved for use.

The project — known as the Accelerated Development of Vaccine Benefit-Risk Collaboration in Europe, or Advance — aims to streamline the compilation of data to determine the benefit-risk profile of already-marketed vaccines and to more quickly communicate those benefits and risks to the public.

In addition to the...
To view the full article, register now.